Tandem Diabetes Care Inc. (NASDAQ:TNDM) shares were up 1.8% on Wednesday . The company traded as high as $8.06 and last traded at $7.99, with a volume of 229,646 shares changing hands. The stock had previously closed at $7.85.

A number of research analysts recently weighed in on TNDM shares. Bank of America Corp. lowered shares of Tandem Diabetes Care from a “neutral” rating to an “underperform” rating in a research report on Thursday, March 24th. Piper Jaffray Cos. restated a “buy” rating and set a $12.00 price objective on shares of Tandem Diabetes Care in a report on Thursday, April 21st. Robert W. Baird restated a “buy” rating on shares of Tandem Diabetes Care in a report on Monday, May 2nd. Zacks Investment Research upgraded shares of Tandem Diabetes Care from a “hold” rating to a “buy” rating and set a $9.25 price objective for the company in a report on Wednesday, May 4th. Finally, Sterne Agee CRT restated a “neutral” rating on shares of Tandem Diabetes Care in a report on Monday, May 16th. One research analyst has rated the stock with a sell rating, two have issued a hold rating and five have issued a buy rating to the company. Tandem Diabetes Care presently has a consensus rating of “Buy” and a consensus price target of $14.21.

The firm’s market capitalization is $240.99 million. The firm has a 50-day moving average of $7.33 and a 200-day moving average of $8.45.

Tandem Diabetes Care (NASDAQ:TNDM) last released its earnings results on Thursday, April 28th. The medical device company reported ($0.68) earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.69) by $0.01. The firm earned $20.06 million during the quarter, compared to analysts’ expectations of $17.67 million. The company’s revenue was up 63.0% compared to the same quarter last year. During the same period in the prior year, the company posted ($0.83) earnings per share. Analysts expect that Tandem Diabetes Care Inc. will post ($2.16) EPS for the current fiscal year.

Tandem Diabetes Care, Inc is a medical device company. The Company is engaged in designing, developing and commercializing products for people with insulin-dependent diabetes. The Company manufactures and sells three insulin pump products, which include t:slim Insulin Delivery System (t:slim), t:flex Insulin Delivery System (t:flex) and t:slim G4 Insulin Delivery System (t:slim G4).

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.